2011

1. Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, Robertson CN, Walther PJ, Polascik TJ, D’Amico AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925-3932.
2. Wang M, Morsbach F, Sander D, Gheorghiu L, Nanda A, Benes CH, Kriegs M, Krause M, Dikomey E, Baumann M, Dahm-Daphi J, Settleman JE, Willers H. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res. 2011.
3. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo H-K, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun Z-Y, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476:346-350.
4. Arvold ND, Niemierko A, Mamon HJ, Fernandez-Del Castillo C, Hong TS. Pancreatic Cancer Tumor Size on CT Scan Versus Pathologic Specimen: Implications for Radiation Treatment Planning. Int. J. Radiat. Oncol. Biol. Phys. 2011;80:1383-1390.
5. Arvold ND, Hsu L, Chen WY, Benzaquen LR, Weiss SE. Marantic Endocarditis With Cardioembolic Strokes Mimicking Leptomeningeal Metastases in Breast Cancer. J Clin Oncol. 2011.
6. Mak RH, McCarthy EP, Das P, Hong TS, Mamon HJ, Hoffman KE. Adoption of preoperative radiation therapy for rectal cancer from 2000 to 2006: a Surveillance, Epidemiology, and End Results Patterns-of-Care Study. Int. J. Radiat. Oncol. Biol. Phys. 2011;80:978-984.
7. Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, Tung N. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. 2011;117:3093-3100.
8. Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J. Clin. Oncol. 2011;29:2619-2627.
9. Trofimov A, Nguyen PL, Efstathiou JA, Wang Y, Lu H-M, Engelsman M, Merrick S, Cheng C-W, Wong JR, Zietman AL. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011;80:928-937.
10. Mak KS, Lee LK, Mak RH, Wang S, Pile-Spellman J, Abrahm JL, Prigerson HG, Balboni TA. Incidence and treatment patterns in hospitalizations for malignant spinal cord compression in the United States, 1998-2006. Int. J. Radiat. Oncol. Biol. Phys. 2011;80:824-831.
11. O’Regan K, Hall M, Jagannathan J, Giardino A, Kelly PJ, Butrynski J, Ramaiya N. Imaging of radiation-associated sarcoma. AJR Am J Roentgenol. 2011;197:W30-36.
12. Cotter SE, Dunn GP, Collins KM, Sahni D, Zukotynski KA, Hansen JL, O’Farrell DA, Ng AK, Devlin PM, Wang LC. Abscopal effect in a patient with metastatic merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity. Arch Dermatol. 2011;147:870-872.
13. Arvold ND, Chen M-H, Moul JW, Moran BJ, Dosoretz DE, Bañez LL, Katin MJ, Braccioforte MH, D’Amico AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J. Urol. 2011;186:91-96.
14. Nguyen PL, Chen M-H, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D’Amico AV, Ennis RD. Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men with High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction. Int J Radiat Oncol Biol Phys. 2011.
15. Margalit DN, Chen Y-H, Catalano PJ, Heckman K, Vivenzio T, Nissen K, Wolfsberger LD, Cormack RA, Mauch P, Ng AK. Technological Advancements and Error Rates in Radiation Therapy Delivery. Int J Radiat Oncol Biol Phys. 2011.
16. Winkfield KM, Niemierko A, Bussiere MR, Crowley EM, Napolitano BN, Beaudette KP, Loeffler JS, Shih HA. Modeling intracranial second tumor risk and estimates of clinical toxicity with various radiation therapy techniques for patients with pituitary adenoma. Technol. Cancer Res. Treat. 2011;10:243-251.
17. Nguyen PL, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH, Pagano M, Loda M. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol. Oncol. 2011;29:302-308.
18. Hattangadi-Gluth JA, Wo JY, Nguyen PL, Abi Raad RF, Sreedhara M, Niemierko A, Freer PE, Georgian-Smith D, Bellon JR, Wong JS, Smith BL, Harris JR, Taghian AG. Basal Subtype of Invasive Breast Cancer is Associated with a Higher Risk of True Recurrence After Conventional Breast-Conserving Therapy. Int J Radiat Oncol Biol Phys. 2011.
19. Winkfield KM, Chen M-H, Dosoretz DE, Salenius SA, Katin M, Ross R, D’Amico AV. Race and Survival Following Brachytherapy-based Treatment for Men With Localized or Locally Advanced Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys. 2011.
20. Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2011;79:1381-1387.
21. Hattangadi JA, Chen M-H, Braccioforte MH, Moran BJ, D’Amico AV. Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. Brachytherapy. 2011.
22. Hu JC, Prasad SM, Gu X, Williams SB, Lipsitz SR, Nguyen PL, Choueiri TK, Choi WW, D’Amico AV. Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011;77:402-406.
23. Nguyen PL, Chen MH, Goldhaber SZ, Martin NE, Beard CJ, Dosoretz DE, Katin MJ, Ross R, Salenius SA, D’Amico AV. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer. 2011;117:406-413.
24. Miyamoto DT, Harris JR. Molecular predictors of local tumor control in early-stage breast cancer. Semin Radiat Oncol. 2011;21:35-42.
25. Mak RH, Halasz LM, Tanaka CK, Ancukiewicz M, Schultz DJ, Russell AH, Viswanathan AN. Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecol. Oncol. 2011;120:101-107.
26. Hoffman KE, Nguyen PL, Chen M-H, Chen RC, Choueiri TK, Hu JC, Kuban DA, D’Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J. Urol. 2011;185:116-120.
27. Westover MB, Westover KD, Bianchi MT. Significance testing as perverse probabilistic reasoning. BMC Med. 2011;9:20.
28. Westover K, Westover MB, Winer E, Richardson A, Iglehart D, Punglia R. Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer? International Journal of Breast Cancer. 2011;2011:973245.
29. Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011;16:886-895.
30. Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard J-AO, Choi NC, Sequist LV. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist. 2011;16:319-326.

2010

31. Winkfield KM, Tsai HK, Yao X, Larson E, Neuberg D, Pomeroy SL, Ullrich NJ, Cohen LE, Kieran MW, Scott RM, Goumnerova LC, Marcus KJ. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer. 2010.
32. Mancias JD, Taghian AG. Accelerated partial breast irradiation using TARGIT: the pros, cons and the need for long-term results. Expert Rev Anticancer Ther. 2010;10:1869-1875.
33. Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2010;78:1081-1085.
34. Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR, Balboni TA, Tishler RB. Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010.
35. Ahove DA, Hoffman KE, Hu JC, Choueiri TK, D’Amico AV, Nguyen PL. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology. 2010;76:1201-1205.
36. Stott SL, Hsu C-H, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. U.S.A. 2010;107:18392-18397.
37. Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence Patterns and Survival for Patients with Intermediate- and High-Grade Myxofibrosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 2010.
38. Halasz LM, Bussière MR, Dennis ER, Niemierko A, Chapman PH, Loeffler JS, Shih HA. Proton Stereotactic Radiosurgery for the Treatment of Benign Meningiomas. Int. J. Radiat. Oncol. Biol. Phys. 2010.
39. Cotter SE, Herrup DA, Friedmann A, Macdonald SM, Pieretti RV, Robinson G, Adams J, Tarbell NJ, Yock TI. Proton Radiotherapy for Pediatric Bladder/Prostate Rhabdomyosarcoma: Clinical Outcomes and Dosimetry Compared to Intensity-Modulated Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2010.
40. O’Regan KN, Nishino M, Armand P, Kelly PJ, Hwang DG-I, Di Salvo D. Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature. J Ultrasound Med. 2010;29:1499-1502.
41. Cotter SE, Devlin PM, Sahni D, Hansen JL, O’Farrell DA, Ng AK, Wang LC. Treatment of cutaneous metastases of Merkel cell carcinoma with surface-mold computer-optimized high-dose-rate brachytherapy. J. Clin. Oncol. 2010;28:e464-466.
42. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J. Clin. Oncol. 2010;28:3958-3964.
43. Truong MT, Nadgir RN, Hirsch AE, Subramaniam RM, Wang JW, Wu R, Khandekar M, Nawaz AO, Sakai O. Brachial plexus contouring with CT and MR imaging in radiation therapy planning for head and neck cancer. Radiographics. 2010;30:1095-1103.
44. Nguyen PL, Chen M-H, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D’Amico AV. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int. J. Radiat. Oncol. Biol. Phys. 2010;77:1046-1052.
45. Miyamoto DT, Mamon HJ, Ryan DP, Willett CG, Ancukiewicz M, Kobayashi WK, Blaszkowsky L, Fernandez-del Castillo C, Hong TS. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int. J. Radiat. Oncol. Biol. Phys. 2010;77:1171-1177.
46. Nguyen PL, D’Amico AV. Deciding which patients to treat with salvage radiotherapy after prostatectomy. Oncology (Williston Park, N.Y.). 2010;24:705, 711.
47. Hoffman KE, Chen M-H, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D’Amico AV. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer. 2010;116:2590-2595.
48. Wo JY, Taghian AG, Nguyen PL, Raad RA, Sreedhara M, Bellon JR, Wong JS, Gadd MA, Smith BL, Harris JR. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int. J. Radiat. Oncol. Biol. Phys. 2010;77:188-196.
49. Nanda A, Chen M-H, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D’Amico AV. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2010;77:147-152.
50. Mak RH, Mamon HJ, Ryan DP, Miyamoto DT, Ancukiewicz M, Kobayashi WK, Willett CG, Choi NC, Blaszkowsky LS, Hong TS. Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Dis. Esophagus. 2010;23:316-323.
51. Katz MS, Efstathiou JA, D’Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The “CaP Calculator”: an online decision support tool for clinically localized prostate cancer. BJU Int. 2010;105:1417-1422.
52. Hoffman KE, Nguyen PL, Ng AK, D’Amico AV. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J. Urol. 2010;183:1798-1802.
53. Choueiri TK, Chen M-H, D’Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010;116:1887-1892.
54. Chen RC, Mamon HJ, Chen Y-H, Gelman RS, Suh WW, Talcott JA, Clark JW, Hong TS. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer. 2010;116:1879-1886.
55. Nanda A, Chen M-H, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D’Amico AV. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:1439-1444.
56. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu C-L, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010;2:25ra23.
57. Dosoretz AM, Chen M-H, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D’Amico AV. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer. 2010;116:837-842.
58. Nguyen PL, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW, D’Amico AV. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:337-341.
59. Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J. Clin. Oncol. 2010;28:136-141.
60. Kahle KT, Kozono D, Ng K, Hsieh G, Zinn PO, Nitta M, Chen CC. Functional genomics to explore cancer cell vulnerabilities. Neurosurg Focus. 2010;28:E5.
61. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda M-del-M, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, D’Andrea A, Chen CC. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS ONE. 2010;5:e10767.

2009

62. Wo JY, Chen M-H, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D’Amico AV. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J. Clin. Oncol. 2009;27:6000-6005.
63. Nguyen PL, Chen RC, Clark JA, Cormack RA, Loffredo M, McMahon E, Nguyen AU, Suh WW, Tempany CM, D’Amico AV. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy. 2009;8:345-352.
64. Arvold ND, Lessell S, Bussiere M, Beaudette K, Rizzo JF, Loeffler JS, Shih HA. Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. Int. J. Radiat. Oncol. Biol. Phys. 2009;75:1166-1172.
65. Martin NE, Ng AK. Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas. Leuk. Lymphoma. 2009;50:1765-1772.
66. Hoffman KE, Yock TI. Radiation therapy for pediatric central nervous system tumors. J. Child Neurol. 2009;24:1387-1396.
67. Lee LJ, Harris JR. Innovations in radiation therapy (RT) for breast cancer. Breast. 2009;18 Suppl 3:S103-111.
68. Nanda A. The forgotten spouse. J. Clin. Oncol. 2009;27:4227-4228.
69. Chen RC, Sadetsky N, Chen M-H, Carroll PR, D’Amico AV. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2009;75:36-39.
70. Nanda A, Chen M-H, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866-873.
71. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J. Clin. Oncol. 2009;27:3916-3922.
72. Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer. 2009;115:3640-3650.
73. Nanda A, Chen M-H, Renshaw AA, D’Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:1419-1423.
74. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA, Whelan TJ, White J, Wo JY, Harris JR. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J. Am. Coll. Surg. 2009;209:269-277.
75. Hoffman KE, McCarthy EP, Recklitis CJ, Ng AK. Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch. Intern. Med. 2009;169:1274-1281.
76. Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int. 2009;104:179-183.
77. Winkfield KM, Harris JR. Effective local therapy and long-term survival in breast cancer. Oncology (Williston Park, N.Y.). 2009;23:669-675.
78. Nguyen PL, Chen M-H, Hoffman KE, Katz MS, D’Amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:104-109.
79. Kozak KR, Adams J, Krejcarek SJ, Tarbell NJ, Yock TI. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:179-186.
80. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 2009;73:1304-1312.
81. Winkfield KM, Linsenmeier C, Yock TI, Grant PE, Yeap BY, Butler WE, Tarbell NJ. Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2009;73:716-721.
82. Nguyen PL, Chen M-H, Catalona WJ, Moul JW, Sun L, D’Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int. J. Radiat. Oncol. Biol. Phys. 2009;73:659-664.
83. Winkfield KM. The Quigless Clinic: its impact on the lives of African Americans living in Tarboro, North Carolina, in the 1950s. J Natl Med Assoc. 2009;101:184-188.
84. Bianchi MT, Alexander BM, Cash SS. Incorporating uncertainty into medical decision making: an approach to unexpected test results. Med Decis Making. 2009;29:116-124.

2008

85. Nguyen PL, Chen M-H, Catalona WJ, Alexander BM, Roehl KA, Loeb S, D’Amico AV. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer. 2008;113:3146-3152.
86. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab. Invest. 2008;88:1340-1348.
87. Nanda A, D’Amico AV. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials. BJU Int. 2008;102:1366-1368.
88. Nanda A, Mamon HJ, Fuchs CS. Sign of Leser-Trélat in newly diagnosed advanced gastric adenocarcinoma. J. Clin. Oncol. 2008;26:4992-4993.
89. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J. Clin. Oncol. 2008;26:4981-4989.
90. Wo JY, Zietman AL. Why does androgen deprivation enhance the results of radiation therapy? Urol. Oncol. 2008;26:522-529.
91. Nanda A, Dias-Santagata DC, Stubbs H, O’Hara CJ, Zaner KS, Lynch TJ, Willers H. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin Lung Cancer. 2008;9:285-287.
92. Hoffman KE, Chen M-H, Punglia RS, Beard CJ, D’Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J. Clin. Oncol. 2008;26:3937-3942.
93. Martin NE, Chen M-H, Catalona WJ, Loeb S, Roehl KA, D’Amico AV. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis. Cancer. 2008;113:717-722.
94. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58:196-213.
95. Nguyen PL, Trofimov A, Zietman AL. Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? Oncology (Williston Park, N.Y.). 2008;22:748-754; discussion 754, 757.
96. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 2008;26:2373-2378.
97. Nguyen PL, D’Amico AV. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J. Clin. Oncol. 2008;26:2055-2056; author reply 2056-2057.
98. Hoffman KE, Hong TS, Zietman AL, Russell AH. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer. 2008;112:943-949.
99. Haglund KE, Viswanathan AN. Computed tomography-based radiation therapy of ovarian remnants for symptomatic persistent endometriosis. Obstet Gynecol. 2008;111:579-583.
100. Chen RC, Clark JA, Manola J, Talcott JA. Treatment “mismatch” in early prostate cancer: do treatment choices take patient quality of life into account? Cancer. 2008;112:61-68.

2007

101. Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, Delaney TF, Shipley WU. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:444-453.
102. Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110:1417-1428.
103. Nguyen PL, Chen M-H, D’Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007;110:1485-1492.
104. Nguyen PL, Zietman AL. High-dose external beam radiation for localized prostate cancer: current status and future challenges. Cancer J. 2007;13:295-301.
105. Kozak KR, Kachnic LA, Adams J, Crowley EM, Alexander BM, Mamon HJ, Fernandez-Del Castillo C, Ryan DP, DeLaney TF, Hong TS. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:1557-1566.
106. Nguyen PL, Chen M-H, Renshaw AA, Sussman B, D’Amico AV. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology. 2007;70:288-293.
107. Alexander BM, Chen M-H, Carroll P, D’Amico AV. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. Urology. 2007;70:320-323.
108. Krejcarek SC, Grant PE, Henson JW, Tarbell NJ, Yock TI. Physiologic and radiographic evidence of the distal edge of the proton beam in craniospinal irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:646-649.
109. Alexander BM, Bryan B, Collins LC, Recht A. Atypical cytology in a persistent seroma following mastectomy for breast cancer: a case report and review of the literature. Breast J. 2007;13:196-199.
110. Krejcarek SC, Chen M-H, Renshaw AA, Loffredo M, Sussman B, D’Amico AV. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer. Urology. 2007;69:515-519.
111. Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, McMahon E, Renshaw AA, Tomaszewski JE, D’Amico AV. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005;103:2053-2059.
112. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol. 2005;23:1507-1513.
113. Margalit DN, Romberg L, Mets RB, Hebert AM, Mitchison TJ, Kirschner MW, RayChaudhuri D. Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl. Acad. Sci. U.S.A. 2004;101:11821-11826.
114. Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, Tempany CM, Titelbaum DS, Schnall MD, Renshaw AA, Tomaszewski JE, D’Amico AV. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004;59:400-405.

Missing publications?